References
Reynolds JEF, editor. Martindale. The Extra Pharmacopoiea XXX. 30th edn. London: The Pharmaceutical Press; 1993. p. 279–80.
Palmer KJ, Brogden RN. Gliclazide, an update of its pharmacological properties and therapeutic efficacy in NIDDM. Drugs 1993;46:92–125.
Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3–12.
Desai KGH, Kulkarni AR, Aminabhavi TM. Solubility of rofecoxib in presence of methanol, ethanol and sodium lauryl sulfate at (298.15, 303.15 and 308.15) K. J Chem Eng Data. 2003;48:942–5.
Harrower AD. Comparison of efficacy, secondary failure rate and complications of sulfonylurea. J Diabetes Complicat. 1994;8:201–3.
Özkan Y, Atay T, Díkman N, Isimer A, Aboul-Enein YH. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin. Pharm Acta Helv. 2000;74:365–70.
Winters S, York P, Timmins P. Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur J Pharm Sci. 1997;5:209–14.
Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin–hydroxypropylmethylcellulose complexes. Die Pharmazie. 2002;57:191–3.
Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release. 1998;51:185–92.
Biswal S, Sahoo J, Murthy PN, Giradkar PR, Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS PharmaSciTech. 2008;9(2):563–70.
Trapani G, Franco M, Latrofa A, Pantaleo MR, Provenzano MR, Sanna E, et al. Physicochemical characterization and in vivo properties of Zolpidem in solid dispersions with polyethylene glycol 4000 and 6000. Int J Pharm. 1999;184:121–30.
Trapani G, Franco M, Latrofa A, Tullio C, Provenzano MR, Serra M, et al. Dissolution properties and anticonvulsant activity of phenytoin–polyethylene glycol 6000 and-polyvinylpyrrolidone K-30 solid dispersions. Int J Pharm. 2001;225:63–73.
Higuchi T, Connors K. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:17–123.
Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustinjns P, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci. 2000;10:311–22.
Khan CA, Rhodes CT. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–9.
Arias MJ, Gines JM, Moyano JR, Rabasco AM. Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols. Pharm Acta Helv. 1996;71:229–35.
Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.
Korsemeyer RW, Gurney R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.
Albertini B, Cavallari C, Passerini N, González-Rodríguez ML, Rodriguez L. Evaluation of b-lactose, PVP K12 and PVP K90 as excipients to prepare piroxicam granules using two wet granulation techniques. Eur J Pharm Biopharm. 2003;56:479–87.
Van den Mooter G, Augustijns P, Blaton N, Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm. 1998;164:67–80.
Khougaz K, Clas SD. Crystallization inhibition in solid dispersion of MK-0591 and poly (vinylpyrrolidone) Polymers. J Pharm Sci. 2000;89(10):1325–34.
Karavas E, Ktistis G, Xenakis A, Georgarakis E. Miscibility behavior and formation mechanism of stabilized felodipine–polyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm. 2005;31:473–89.
Ford JL. The current status of solid dispersions. Pharm Acta Helv. 1986;61:69–88.
Bettinetti GP, Mura P, Giordano F, Setti M. Thermal behaviour and physico-chemical properties of naproxen in mixtures with polyvinylpyrrolidone. Thermochim Acta. 1991;199:165–71.
Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267:79–91.
Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm. 1999;18:143–51.
Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm. 2004;30(3):303–17.
Nair R, Gonen S, Hoag SW. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int J Pharm. 2002;240:11–22.
Hosono T, Tsuchiya S, Matsumura H. Model of interaction of ajmaline with polyvinylpyrrolidon. J Pharm Sci. 1980;69:824–6.
Najib NM, Suleiman M, Malakh A. Characteristics of the in vitro release of ibuprofen from polyvinylpyrrolidone solid dispersions. Int J Pharm. 1986;32:229–36.
Acknowledgments
The authors are grateful to Aristo Pharmaceuticals Pvt. Ltd, Mumbai, India. Mr. S. Biswal acknowledges the Principal of the Royal College of Pharmacy and Health Sciences, Brahmapur, for providing the necessary facilities.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Biswal, S., Sahoo, J. & Murthy, P.N. Physicochemical Properties of Solid Dispersions of Gliclazide in Polyvinylpyrrolidone K90. AAPS PharmSciTech 10, 329–334 (2009). https://doi.org/10.1208/s12249-009-9212-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-009-9212-7